Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add exenatide versus switch to exenatide in inadequately controlled type 2 diabetes on sitagliptin plus metformin
2008-006317-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to Week 20. Started Dec 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006317-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006317-25.